Publication
2nd Circuit defers to executive will on application of sovereign immunity
The Second Circuit recently held that federal common law protections of sovereign immunity did not preclude prosecution of a state-owned foreign corporation.
Author:
United States | Publication | January 2021
On December 23, 2020, Governor Tim Walz signed three emergency executive orders regarding the state’s COVID-19 response.
Emergency Executive Order 20-107 authorizes out-of-state pharmacists—who hold an active, relevant license, certificate or other permit in good standing issued by a state of the United States or the District of Columbia—to administer COVID-19 vaccines in Minnesota during the COVID-19 Peacetime Emergency.
Additionally, Emergency Executive Order 20-106 rescinds Executive Order 20-34, which directed the Minnesota Commissioner of Health to share limited health information—the addresses where a positive COVID-19 test result has been obtained and whether the individual tested is still contagious to others—with the Department of Public Safety. Executive Order 20-106 also rescinds Executive Order 15-15, which established the Governor’s Committee to advise the Minnesota Pollution Control Agency (MPCA). The Committee was tasked with providing input and recommendations prior to certain regulatory decisions made by the MPCA.
Finally, Emergency Executive Order 20-105 extends a 10 percent salary reduction for the Governor and his Chief of Staff through July 1, 2021.Publication
The Second Circuit recently held that federal common law protections of sovereign immunity did not preclude prosecution of a state-owned foreign corporation.
Publication
Facing the fast-growing development of AI across the globe, particularly Generative AI (GenAI), the G7 competition authorities and policymakers (Canada, France, Germany, Japan, Italy, the UK and the US) and the European Commission met in Italy on 3-4 October 2024 to discuss the main competition challenges raised by these new technologies in digital markets.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023